Drug Trial Radar · NCT03750383
Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects
Last checked: Nov 19, 2026Latest source record: Feb 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Nov 2, 2018
Primary completion
Nov 17, 2018
Study completion Dec 13, 2018
Sponsor
- Lead sponsor
- Enanta Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- Collaborators
- Pharmaceutical Research Associates
- First posted
- Nov 23, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Non-Randomized, Open-Label, Two-Part, Drug-Drug Interaction Study to Evaluate the Effects of Cyclosporine and Prednisone on the Pharmacokinetics and Safety of EDP-938 in Healthy Adult Subjects
Conditions
- RSV Infection
Interventions
EDP-938Drug
Subjects will receive EDP-938 once daily on Day 1 and Day 5 (Part 1)
EDP-938Drug
Subjects will receive one dose of EDP-938 on Day 1 and Day 8 (Part 2)
CyclosporineDrug
Subjects will receive one dose of cyclosporine on Day 5
PrednisoneDrug
Subjects will receive prednisone once daily from Day 5 to Day 14
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax of EDP-938 with and without coadministration with cyclosporineTime frame: Up to 12 days
- AUC of EDP-938 with and without coadministration with cyclosporineTime frame: Up to 12 days
- Cmax of EDP-938 with and without coadministration with prednisoneTime frame: Up to 21 days
- AUC of EDP-938 with and without coadministration with prednisoneTime frame: Up to 21 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pharmaceutical Research Associates, Inc.,
Lenexa, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.